- Collaboration to Preserve Sight partners from Indonesia, Vietnam and the Philippines gathered anew in a virtual forum titled “How can 2030 In Sight support eye health beyond Covid?”
- Convened by the International Agency for Prevention of Blindness (IAPB) in collaboration with Novartis, the virtual forum aims to consolidate partners’ efforts in building on the key takeaways from the one-year Collaboration to Preserve Sight results.
- The Collaboration to Preserve Sight initiative has revealed many opportunities to reshape the whole healthcare system in general and shift health priorities to eyecare services in particular.
January 27, 2022 – Collaboration to Preserve Sight partners from the Fred Hollows Foundation (Vietnam and Philippines), Vitreo-Retina Society of the Philippines, Perdami (Indonesia), and National Committee for Sight Preservation (Philippines) gathered anew in a virtual forum titled “How can 2030 In Sight support eye health beyond Covid?”. Convened by the International Agency for Prevention of Blindness (IAPB) in collaboration with Novartis, the virtual forum aims to consolidate partners’ efforts in building on the key takeaways from the one-year Collaboration to Preserve Sight results.
“2030 In Sight is the IAPB strategic plan to ending avoidable sight loss for the next decade.¹ It takes the evidence and know-how generated over the past 30 years, leverages the significant political momentum that eye health stakeholders have generated and lays out an ambitious approach that will guide their work until 2030 and beyond,” said Ms. Amanda Davis, Chairperson, International Agency for Prevention of Blindness (IAPB), Western Pacific.
Its three key objectives are by 2030, (1) no one experiences unnecessary or preventable sight loss and everyone can achieve their full potential; (2) eyecare and rehabilitation services are accessible, inclusive and affordable to everyone, everywhere, whenever they are needed; and (3) people understand the importance of caring for their own eye health and demand access to services, free from the weight of any social stigma.²
Eyecare challenges during the pandemic
Challenges identified during the initial implementation of the initiative include de-prioritization of eye health, with health facilities focusing on treating COVID-19 patients or increasing vaccination coverage, which resulted in limited access for other patients; non-COVID patients avoiding hospitals due to fear of being infected; and lack of educators to communicate and promote eye health, especially in rural areas.
“The pandemic has greatly worsened existing inequalities in access to eyecare services.,” said Dr. Noel Chua, Chairperson, National Committee for Sight Preservation (NCSP).
Opportunities to enhance eyecare services
On the positive side, the Collaboration to Preserve Sight initiative has revealed many opportunities to reshape the whole healthcare system in general and shift health priorities to eyecare services in particular.
“To this end, eyecare policies need to be innovative and adaptable to different settings and dynamic conditions. Strong partnerships with government and other key stakeholders are vital to raise public awareness in eye health and enhance eyecare services,” said Dr Phuc Huynh, Vietnam Cluster Head, The Fred Hollows Foundation.
Eyecare initiatives implemented during the pandemic
As of December 2021, the Collaboration to Preserve Sight initiative has reached one million people through awareness initiatives; screened 78,000 patients; detected vision impairment among 11,000 patients; facilitated 7 out of 10 diagnosed patients to seek consultation; treated 6 of 10 patients or over 4,700 patients; launched social media platforms for patient education and screening schedules; and formed external partnerships with over 370 patient and medical organizations, NGOs and policymakers.
“We thank our partners for enabling the Collaboration to Preserve Sight initiative to have a meaningful impact, with 6 out of 10 people in vulnerable communities seeking consultation and receiving treatment despite pandemic restrictions. The initiative demonstrates that intensified screening coupled with innovative patient education facilitates the patient journey to sight preservation,” said Ms. Christine Fajardo, Asia Cluster Patient Engagement Lead and Corporate Affairs Head for Novartis Healthcare Philippines, Inc.
Based on the learnings from the initiative’s implementation in the three countries during the pandemic, the forum aims to generate recommendations on how to provide equitable access to eyecare services beyond COVID-19 in underserved communities in Indonesia, the Philippines, and Vietnam. It also seeks to start a policy dialogue on getting national support for eyecare initiatives and recommendations, as well as build alliances with media in communicating recommendations and facilitating concerted action for universal eye health.
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact [email protected]
About IAPB
Founded in 1975, the International Agency for Prevention of Blindness (IAPB) is the overarching alliance for the global eye health sector, with more than 150 organizations in over 100 countries working together for a world where everyone has universal access to eye care. IAPB believes in a world in which no one is needlessly visually impaired, where everyone has access to the best possible standard of eye health; and where those with irreparable vision loss achieve their full potential.
Novartis Media Relations:
| Philippines [email protected] [email protected] |
Indonesia [email protected] [email protected] |
Vietnam [email protected] |
References:
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.